Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review
Authors:
- Girolamo RanieriGirolamo Ranieri
- Marianna PantaleoMPMarianna Pantaleo
- Mariagrazia PiccinnoMPMariagrazia Piccinno
- Maria RoncettiMRMaria Roncetti
- Maddalena MutinatiMMMaddalena Mutinati
- Ilaria MarechIMIlaria Marech
- Rosa PatrunoRPRosa Patruno
- Annalisa RizzoARAnnalisa Rizzo
- Raffaele Luigi SciorsciRSRaffaele Luigi Sciorsci
- 1 November 2013
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 88 (2) , 293-308
Abstract
No abstract availableKeywords
This publication has 175 references indexed in Scilit:
- Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targetingMolecular Immunology, 2012
- Update on mammography trendsCancer, 2010
- Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)European Journal of Cancer, 2010
- Urban–rural differences in breast cancer incidence by hormone receptor status across 6 years in EgyptBreast Cancer Research and Treatment, 2009
- Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cellsBritish Journal of Cancer, 2009
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerBritish Journal of Cancer, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002